Business
Result of Annual General Meeting
Result of Annual General Meeting.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 1331G hVIVO plc 24 May 2017 \n\nFor immediate release 2.00pm: 24 May 2017\n \nHVIVO PLC\n(\"hVIVO\" or the \"Company\")\n \nResult of Annual General Meeting\n \nhVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, is pleased to announce that all resolutions proposed at its Annual General Meeting, held at 10.00am on 24 May 2017, were duly passed.\n \nFor further information please contact: \n \n\n\n\n\nhVIVO plc \n\n\n+44 207 756 1300 \n\n\n\n\nKym Denny (Chief Executive Officer) \n\n\n \n\n\n\n\nGraham Yeatman (Chief Financial & Business Officer) \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nNumis Securities Limited\n\n\n +44 207 260 1000 \n\n\n\n\nMichael Meade / Freddie Barnfield (Nominated Adviser) \n\n\n \n\n\n\n\nJames Black / Michael Burke (Corporate Broking) \n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nFTI Consulting \n\n\n \n\n\n\n\nSimon Conway / Victoria Foster Mitchell (UK)\n\n\n+44 203 727 1000\n\n\n\n\nJohn Capodanno / Evan Smith (US)\n\n\n+1 212 850 5705\n\n\n\n\n \n \nNotes to Editors: \nhVIVO plc (\"hVIVO\"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.\n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END AGMUSSURBUAVUAR\n ","length":4752,"tagName":"div"}]